Amgen's Repatha shows 20% lower mortality risk in 12,000-patient study

PR Newswire+2 · 6 hours ago

Amgen's Repatha shows 20% lower mortality risk in 12,000-patient study

Amgen said Repatha reduced mortality risk by 20% in a study of more than 12,000 high-risk patients.
Dynagas LNG Partners scheduled the release of its Q2 and H1 2026 results for after the New York market close on Sept. 7.
The I-66 Slugging Challenge and a new Northern Virginia-to-Washington corridor are scheduled to launch Sept. 14.

Quotes

“Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.”— Amgen

Sources